Blog

Jan 23, 2025, 20:48

Gustavo Viani: Can SBRT delay systemic therapy chances in oligoprogressive cancer?

Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, University of Sao Paulo, shared a post on LinkedIn:

“Can SBRT delay systemic therapy chances in oligoprogressive cancer?

Objective

• Assess SBRT’s ability to delay systemic therapy (ST) changes in patients with ≤5 progressing sites under ST

Methods

• 70 patients (GU, breast, GI cancers)
• Intervention: SBRT (1-5 fr) + continued ST
• Endpoints: ST changes, survival, toxicity, QuoL

Outcomes

•ST Changes: Avoided by 46% at 1 year.
•PFS: GU (4.8m), breast (6.5m), GI (3.2m)
•OS: GU 86%, breast 96%, GI 22% at 1 y
•Toxicity: Minimal side effects. N

Gr4+ Takeaway SBRT offers a safe, effective option for delaying ST changes, especially in GU and breast cancers.”

The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial

Authors: Rachel M Glicksman et al.

Gustavo Viani

Aisling Barry Ali Hosni Andrew Hope cancer Ciara O'Brien Eric Chen Joanna Javor Joelle Helou Laura A Dawson OncoDaily Oncology Patricia Lindsay Peter Chung Philippe L. Bedard Rachel M. Glicksman Rebecca Wong Scott Bratman Srinivas Raman Xiang Y Ye

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director